Insider Buying: Greenwich LifeSciences (NASDAQ:GLSI) CEO Purchases $38,502.00 in Stock
Greenwich LifeSciences CEO Snehal Patel purchased 4,600 shares of the company's stock at $8.37 per share, totaling $38,502. This transaction increased his ownership by 0.08%, now holding 5,588,102 shares valued at $46,772,413.74. The purchase was disclosed in an SEC filing. Patel has made other recent purchases, including 10,600 shares on November 7th and 2,300 shares on October 31st. The stock has a 52-week range of $7.78 to $15.47 and a market cap of $120.61 million.
Greenwich LifeSciences, Inc. (NASDAQ:GLSI - Get Free Report) CEO Snehal Patel acquired 4,600 shares of the firm's stock in a transaction on Tuesday, November 25th. The stock was purchased at an average cost of $8.37 per share, with a total value of $38,502.00. Following the completion of the transaction, the chief executive officer owned 5,588,102 shares in the company, valued at $46,772,413.74. The trade was a 0.08% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available at this link.
Snehal Patel also recently made the following trade(s):
- On Friday, November 7th, Snehal Patel acquired 10,600 shares of Greenwich LifeSciences stock. The shares were acquired at an average price of $8.43 per share, with a total value of $89,358.00.
- On Friday, October 31st, Snehal Patel bought 2,300 shares of Greenwich LifeSciences stock. The stock was acquired at an average cost of $9.26 per share, for a total transaction of $21,298.00.
Get Greenwich LifeSciences alerts:
Greenwich LifeSciences Trading Up 4.3%
Greenwich LifeSciences stock opened at $8.71 on Friday. Greenwich LifeSciences, Inc. has a 52 week low of $7.78 and a 52 week high of $15.47. The stock has a market cap of $120.61 million, a P/E ratio of -5.93 and a beta of 1.61. The stock has a 50 day moving average of $9.50 and a 200-day moving average of $10.23.
Greenwich LifeSciences (NASDAQ:GLSI - Get Free Report) last posted its quarterly earnings results on Friday, November 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.30). As a group, equities analysts predict that Greenwich LifeSciences, Inc. will post -0.8 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Greenwich LifeSciences
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Police & Firemen s Retirement System of New Jersey acquired a new stake in shares of Greenwich LifeSciences during the 2nd quarter worth approximately $25,000. Bank of America Corp DE grew its holdings in Greenwich LifeSciences by 22.3% in the 4th quarter. Bank of America Corp DE now owns 7,262 shares of the company's stock worth $82,000 after buying an additional 1,322 shares in the last quarter. Rhumbline Advisers increased its position in Greenwich LifeSciences by 48.7% in the 1st quarter. Rhumbline Advisers now owns 9,673 shares of the company's stock valued at $92,000 after acquiring an additional 3,168 shares during the period. HighTower Advisors LLC bought a new stake in Greenwich LifeSciences during the 1st quarter valued at $147,000. Finally, Strs Ohio bought a new position in shares of Greenwich LifeSciences in the first quarter worth $177,000. 4.16% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
GLSI has been the subject of a number of research reports. Noble Financial initiated coverage on Greenwich LifeSciences in a research note on Wednesday, August 20th. They issued an "outperform" rating and a $45.00 price target for the company. Weiss Ratings reiterated a "sell (e+)" rating on shares of Greenwich LifeSciences in a research report on Tuesday, October 14th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $42.00.
View Our Latest Report on Greenwich LifeSciences
About Greenwich LifeSciences
(Get Free Report)Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.
Recommended Stories
- Five stocks we like better than Greenwich LifeSciences
- Which Wall Street Analysts are the Most Accurate?
- 3 Stocks to Buy for the Evolution of AI Infrastructure
- What is a Death Cross in Stocks?
- How Semtech’s Data Center Chips Are Powering the AI Boom
- How to Invest in Insurance Companies: A Guide
- Keysight Technologies' Surge: The Market Wakes Up to This AI Play
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Greenwich LifeSciences Right Now?
Before you consider Greenwich LifeSciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Greenwich LifeSciences wasn't on the list.
While Greenwich LifeSciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
